Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Biotech
Astellas closes stem cell unit’s Seattle site, layoffs incoming
Astellas is preparing to close its Seattle site for its stem cell therapy unit, with around 55 employees set to be affected.
James Waldron
Apr 14, 2026 10:45am
Astellas says 'I do' to Vir's T-cell engager in $1.7B deal
Feb 23, 2026 5:00pm
Fierce Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Feb 5, 2026 11:00am
Fierce Pharma
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Ocugen update charts course for rivalry with Apellis, Astellas
Jan 15, 2026 9:22am
Astellas turns down option to license Taysha gene therapy—again
Oct 17, 2025 10:50am
